QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)

DICE Therapeutics (DICE) Competitors

$32.58
+0.05 (+0.15%)
(As of 06/8/2023 ET)
Compare
Today's Range
$31.48
$32.89
50-Day Range
$25.86
$38.24
52-Week Range
$12.64
$45.99
Volume
290,997 shs
Average Volume
457,860 shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.60

DICE vs. NUVL, JANX, VYGR, FATE, TNYA, CMPX, BHVN, FNA, EMBC, and ADUS

Should you be buying DICE Therapeutics stock or one of its competitors? The main competitors of DICE Therapeutics include Nuvalent (NUVL), Janux Therapeutics (JANX), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Tenaya Therapeutics (TNYA), Compass Therapeutics (CMPX), Biohaven (BHVN), Paragon 28 (FNA), Embecta (EMBC), and Addus HomeCare (ADUS). These companies are all part of the "medical" sector.

DICE Therapeutics vs.

Nuvalent (NASDAQ:NUVL) and DICE Therapeutics (NASDAQ:DICE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking.

91.5% of DICE Therapeutics shares are owned by institutional investors. 14.8% of Nuvalent shares are owned by insiders. Comparatively, 4.9% of DICE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nuvalent currently has a consensus target price of $44.50, suggesting a potential upside of 4.73%. DICE Therapeutics has a consensus target price of $62.60, suggesting a potential upside of 92.14%. Given DICE Therapeutics' higher possible upside, analysts plainly believe DICE Therapeutics is more favorable than Nuvalent.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvalent
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
DICE Therapeutics
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.91

Nuvalent has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, DICE Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

In the previous week, Nuvalent had 3 more articles in the media than DICE Therapeutics. MarketBeat recorded 9 mentions for Nuvalent and 6 mentions for DICE Therapeutics. DICE Therapeutics' average media sentiment score of 0.82 beat Nuvalent's score of 0.12 indicating that DICE Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvalent
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DICE Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DICE Therapeutics received 10 more outperform votes than Nuvalent when rated by MarketBeat users. However, 55.56% of users gave Nuvalent an outperform vote while only 48.39% of users gave DICE Therapeutics an outperform vote.

CompanyUnderperformOutperform
NuvalentOutperform Votes
5
55.56%
Underperform Votes
4
44.44%
DICE TherapeuticsOutperform Votes
15
48.39%
Underperform Votes
16
51.61%

Nuvalent has higher earnings, but lower revenue than DICE Therapeutics. Nuvalent is trading at a lower price-to-earnings ratio than DICE Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuvalentN/AN/A-$81.85 million-$1.72-24.70
DICE Therapeutics$1.13 million1,376.14-$83.89 million-$2.18-14.94

DICE Therapeutics' return on equity of -22.01% beat Nuvalent's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvalent N/A -25.63% -24.59%
DICE Therapeutics N/A -22.01% -20.70%

Summary

DICE Therapeutics beats Nuvalent on 9 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DICE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DICE vs. The Competition

MetricDICE TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.56B$6.07B$4.62B$6.27B
Dividend YieldN/A2.59%2.37%6.44%
P/E Ratio-14.946.16111.0313.34
Price / Sales1,376.14153.263,466.81100.76
Price / CashN/A20.6291.55107.03
Price / Book2.744.844.725.31
Net Income-$83.89M$194.50M$117.72M$192.96M
7 Day Performance7.31%2.61%2.74%4.03%
1 Month Performance-14.51%1.34%2.13%5.34%
1 Year Performance124.84%14.74%11.17%1.86%

DICE Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NUVL
Nuvalent
0.9352 of 5 stars
$43.65
-0.7%
$44.50
+1.9%
+336.2%$2.48BN/A-25.3870Insider Selling
News Coverage
JANX
Janux Therapeutics
0.6673 of 5 stars
$13.75
-1.5%
$28.33
+106.1%
+30.5%$575.16M$8.61M-8.4962
VYGR
Voyager Therapeutics
2.7012 of 5 stars
$12.57
+7.3%
$16.00
+27.3%
+122.0%$547.30M$40.91M5.51125
FATE
Fate Therapeutics
1.7497 of 5 stars
$5.52
+7.0%
$15.50
+180.8%
-77.5%$543.06M$96.30M-2.28551
TNYA
Tenaya Therapeutics
1.7593 of 5 stars
$7.58
-0.3%
$18.00
+137.5%
+23.3%$506.88MN/A-3.07141
CMPX
Compass Therapeutics
2.373 of 5 stars
$3.11
+2.6%
$9.05
+191.0%
+22.0%$393.45MN/A-8.6426
BHVN
Biohaven
2.1132 of 5 stars
$22.65
+4.6%
$38.39
+69.5%
-84.4%$1.55B$462.51M-1.84928Analyst Report
FNA
Paragon 28
2.1695 of 5 stars
$18.83
+2.3%
$27.67
+46.9%
+4.0%$1.55B$181.38M-21.40343Insider Selling
Positive News
EMBC
Embecta
1.5359 of 5 stars
$27.16
+3.6%
$26.50
-2.4%
+1.7%$1.56B$1.13B16.762,029
ADUS
Addus HomeCare
2.6422 of 5 stars
$93.84
+0.4%
$112.75
+20.2%
+12.3%$1.52B$951.12M30.2733,182Positive News

Related Companies and Tools

This page (NASDAQ:DICE) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -